Editas Medicine Inc [EDIT] stock prices are up 9.64% to $2.16 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The EDIT shares have gain 11.92% over the last week, with a monthly amount glided 54.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Editas Medicine Inc [NASDAQ: EDIT] stock has seen the most recent analyst activity on April 28, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $3. Previously, JP Morgan downgraded its rating to Underweight on December 16, 2024. On December 13, 2024, downgrade downgraded it’s rating to Hold. Stifel downgraded its rating to a Hold and decreased its price target to $3 on December 13, 2024. Chardan Capital Markets downgraded its rating to a Neutral. Wells Fargo downgraded its rating to Equal Weight for this stock on December 11, 2024, and downed its price target to $4. In a note dated November 25, 2024, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $13 to $1.
The stock price of Editas Medicine Inc [EDIT] has been fluctuating between $0.91 and $6.05 over the past year. Currently, Wall Street analysts expect the stock to reach $12.85 within the next 12 months. Editas Medicine Inc [NASDAQ: EDIT] shares were valued at $2.16 at the most recent close of the market. An investor can expect a potential return of 494.91% based on the average EDIT price forecast.
Analyzing the EDIT fundamentals
The Editas Medicine Inc [NASDAQ:EDIT] reported sales of 35.84M for trailing twelve months, representing a surge of 310.40%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -5.91%, Pretax Profit Margin comes in at -8.06%, and Net Profit Margin reading is -8.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.95, Equity is -1.66 and Total Capital is -0.97. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.5.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.0000 points at the first support level, and at 1.8300 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.2600, and for the 2nd resistance point, it is at 2.3600.
Ratios To Look Out For
It’s worth pointing out that Editas Medicine Inc [NASDAQ:EDIT]’s Current Ratio is 3.08. On the other hand, the Quick Ratio is 3.08, and the Cash Ratio is 1.9. Considering the valuation of this stock, the price to sales ratio is 5.05, the price to book ratio is 2.90.
Transactions by insiders
Recent insider trading involved Parison Amy, SVP, Chief Financial Officer, that happened on Jun 03 ’25 when 446.0 shares were sold. EVP, CHIEF SCIENTIFIC OFFICER, Burkly Linda completed a deal on Jun 03 ’25 to sell 726.0 shares. Meanwhile, CEO O’Neill Gilmore Neil sold 15192.0 shares on Jun 03 ’25.
